Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
All News
Article
Article
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
Article
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Article
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more...
https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Do B-cell targeted therapies still have a place for the treatment of Sjogren’s? #EULAR2021
https://t.co/96sv3beMvG https://t.co/EWKCA1KGsC
Current approach to lupus and pregnancy by Dr. Robert Chao ( @doctorRBC) #EULAR2021
https://t.co/eFd6j9YZo5 https://t.co/tW9tJIRpjm
Video: What Kind of Diet Should You be on? with Dr. Robert Chao ( @doctorRBC)
https://t.co/jqkA8vrgww
#EULAR2021 https://t.co/5mPuZWmw20
#EULAR2021 - Day 3 Report
https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow.
https://t.co/sut3zubcow https://t.co/f7XDuRyLB9
RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021
In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment.
https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl
Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021
https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof
Time to go raspberry picking?
Rubus idaeus leaf extract 400mg and 200mg after 12 weeks
⬇️ VAS pain in knee OA compared to placebo
⭐️no effect on WOMAC, SF-36, 20m walking
Abs#POS0281
#EULAR2021 @RheumNow https://t.co/QAiag2XjRh
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
LNA043 - modified, recombinant human angiopoietin-like 3 (ANGPTL3) protein
⭐️proof of concept trial on patients with articular cartilage lesions
⭐️regeneration of damaged cartilage
⭐️treatment effect in cartilage volume
⭐️phase IIb pending
Abs#POS0277
#EULAR2021 @RheumNow
#EULAR2021 Pres6882 @Rheumnow. Excellent summary slide by Dr. Elena Nikiphorou with 10 great take-home messages to share with your patient on diet and rheumatic disease. https://t.co/N7mq73KzLF


